Suscribirse

Subdermal Contraceptive Implant Insertion Trends and Retention in Adolescents - 30/04/21

Doi : 10.1016/j.jpag.2020.12.019 
Nichole Tyson, MD 1, 2, , MaryAlice Lopez, MD 3, 4, Maqdooda Merchant, MSc, MA 5, Debbie Postlethwaite, RNP, MPH 5
1 Department of Obstetrics and Gynecology, Kaiser Permanente, Roseville, California 
2 Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California 
3 Department of Obstetrics and Gynecology, Kaiser Permanente, Oakland, California 
4 Women's Health Associates, Boise, Idaho 
5 Division of Research, Kaiser Permanente, Oakland, California 

Address correspondence to: Nichole Tyson, MD, Department of Obstetrics and Gynecology, Stanford University School of Medicine, 300 Pasteur Drive Room HG332, Stanford, CA 94305-5317; Phone (650) 646-4422Department of Obstetrics and GynecologyStanford University School of Medicine300 Pasteur Drive Room HG332StanfordCA94305-5317

Abstract

Study Objective

There is growing advocacy for use of long-acting reversible contraception among sexually active adolescents. Our primary aims were to evaluate the etonogestrel subdermal contraceptive implant (SCI) insertion trends among adolescents, as well as SCI retention at 1, 2, and 3 years, indications for removal, and to identify pregnancies that occurred during SCI use.

Design, Setting, Participants, Interventions, and Main Outcome Measures

A retrospective cohort study was conducted of adolescents aged 13-19 years with SCI insertions in 2008-2014 within a large integrated health care system. Demographic and clinical characteristics included age, race/ethnicity, body mass index, gravidity, parity, insertions, reinsertions, indications for removal, and pregnancy. Electronic medical record review was conducted on a randomized sample of 540 adolescents with insertions during 2008-2011 for the retention objective to validate electronically extracted variables. Analyses included descriptive statistics, survival analysis with Kaplan-Meier estimates for implant retention and Cochran-Armitage trend test for insertions according to year during 2008-2014.

Results

Most adolescent SCI users were non-Hispanic white (43%), or Hispanic (34.2%) and 16 years or older (84.2%) at the time of insertion. Overall, 1-, 2-, and 3-year retention rates were 78.6%, 59.4%, and 26.2%, respectively, with retention at 44.3% at 2 years 9 months (indicative of removal of method for near expiration of 3-year device). The insertion rate trend showed statistically significant increases annually, from 0.14% in 2008 to 0.91% in 2014; P < .0001. No pregnancies were documented during implant use. The most common indication for SCI removal was device expiration.

Conclusion

SCI insertions increased annually among adolescents, with more than a sixfold increase over the 6-year study period, and more than half of the SCIs were retained through 2 years of use. The most common indication of SCI removal was completion of Food and Drug Administration-approved duration.

El texto completo de este artículo está disponible en PDF.

Key Words : Nexplanon, LARC, Long-acting reversible contraception, Implant, Adolescent, Teen, Contraception counseling, Birth control


Esquema


 The authors indicate no conflicts of interest.


© 2020  North American Society for Pediatric and Adolescent Gynecology. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 34 - N° 3

P. 348-354 - juin 2021 Regresar al número
Artículo precedente Artículo precedente
  • “It's Worked Well for Me”: Young Women's Reasons for Choosing Lower-Efficacy Contraceptive Methods
  • Nancy F. Berglas, Katrina Kimport, Aisha Mays, Shelly Kaller, M. Antonia Biggs
| Artículo siguiente Artículo siguiente
  • Intrauterine Devices and Sexually Transmitted Infection among Older Adolescents and Young Adults in a Cluster Randomized Trial
  • Alison M. El Ayadi, Corinne H. Rocca, Sarah H. Averbach, Suzan Goodman, Philip D. Darney, Ashlesha Patel, Cynthia C. Harper

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.